Cortistatin as a modulator of inflammatory and mitochondrial dysfunction in Huntington's disease.
Cortistatin, a natural brain molecule, reduces both inflammation and energy-factory damage in Huntington's disease models, opening a novel therapeutic avenue.
This Journal of Neuroinflammation study characterized cortistatin's role in attenuating the two major pathophysiological processes driving Huntington's disease (HD)—neuroinflammation and mitochondrial dysfunction—using cellular and in vivo HD models. The findings position cortistatin as a novel endogenous modulator with therapeutic potential in HD, an autosomal dominant rare neurodegenerative disease affecting approximately 30,000 Americans with no approved disease-modifying treatment.
What the study was
- Study design
- preclinical_in_vivo
- Population
- Huntington's disease mouse and cellular models
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- J Neuroinflammation
Why it surfaced
Novel therapeutic mechanism for Huntington's disease, a rare autosomal dominant neurodegenerative condition with high unmet need and no disease-modifying therapies; cortistatin targets two key HD pathomechanisms simultaneously (neuroinflammation + mitochondrial dysfunction); preliminary but methodologically sound preclinical study.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.